APIRx

THE WORLD'S FIRST AND ONLY END-TO-END cGMP PRODUCTS WITH Naturally-Extracted Cannabinoids

APIRx is the world’s only cGMP (current Good Manufacturing Practice) cannabis plant users and providers of cGMP API’s based on naturally extracted cannabinoids.

We produce just as pure product as synthetic cannabinoids, but from a natural source with minimum or no alteration of the cannabinoids, leading to healthier, safer and more effective cannabinoid-based medicines and products.

Find Out More

OUR API PRODUCTS Our Cannabis Plant Cultivation

APIRx’s operational process begins with the procurement of the cGMP-produced flowers of the cannabis sativa. These will be processed into stable API’ utilizing APIRx proprietary methodology.

We are the licensor of proprietary active pharmaceutical ingredients (API’s) for extraction, purification and microencapsulation from cGMP-produced Cannabis plants; and the manufacturer and marketer of Cannabis based pharmaceutical, nutraceutical, cosmetic and OTC products based on end-to-end cGMP process certification.

PARTNER WITH A BEST-IN-CLASS TEAM Rooted in Advantageous Economics

Our independent Board of Directors is comprised of leading authorities in relevant industry sectors, providing objective perspective, strategic direction and network connections.

Partner with Us

WHO WE ARE

APIRx is a leading pharmaceutical company specialized in cannabinoid active pharmaceutical ingredients (APIs) and drug products, which contain these APIs.

LEARN MORE >

WHAT WE DO

Our products are manufactured under the cGMP (current Good Manufacturing Practice) conditions from the highest quality natural extracts of cannabis sativa plant.

LEARN MORE >

WHY PARTNER WITH US

We can provide your business with pure cannabinoids (99.9% pure) or dissolved in ethanol or in an appropriate oil with the concentration of an active ingredient.

LEARN MORE >

OUR MISSION & VISION End-to-End cGMP Cannabis APIs

APIRx was born out of the growing need for cannabinoid-based solutions for wound healing, dermatological diseases, medication-related osteonecrosis of the jaws (MRONJ), appetite control and others.

To date, only synthetically produced cannabinoids have received cGMP certification–but these are quite expensive and artificial. APIRx’s products will be cGMP based on 100% natural cannabis plant product.

At APIRx, we believe that the market is headed in the natural cGMP direction from a regulatory compliance and from the demand for better, safer, and environmentally friendlier products.

Our motto is: “As pure as synthetic, but natural!”

About us

THERAPEUTIC EFFECT ON DISEASES Emerging Clinical Applications

According to WebMD, approximately 100 million in the U.S. suffer from chronic pain. APIRx produces cannabinoid-based pharmaceuticals and offers state of the art technologies for clients in need of cannabinoid-based Active Pharmaceutical Ingredients, as well as final product manufacturing.

According to New Frontier Data, the current market projections for the U.S. Cannabis industry is as follows: In 2017, the U.S. medical market was priced at $5.1 billion with projections for 2025 expected to reach $12 billion.

2017

2025

LEARN MORE INFORMATION ABOUT THE INDUSTRY FROM OUR RESEARCH AND DISCOVERIES

EXPLORE NOW

JOIN THE MOST DEDICATED TEAM OF SCIENTISTS & CLIENTS

Partner With Us

THE WORLD'S FIRST AND ONLY END-TO-END cGMP PRODUCTS WITH Naturally-Extracted Cannabinoids

WHO WE ARE

WHAT WE DO

WHY PARTNER WITH US

OUR MISSION & VISION End-to-End cGMP Cannabis APIs

THERAPEUTIC EFFECT ON DISEASES Emerging Clinical Applications

JOIN THE MOST DEDICATED TEAM OF SCIENTISTS & CLIENTS

Contact Us SEND US A MESSAGE AND A TEAM MEMBER WILL BE RIGHT WITH YOU